semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Breast Cancer Sentinel Lymph Node Women ≥ 19 years Invasive unilateral breast carcinoma with histological confirmation History of invasive breast cancer Histologically or radiologically no suspicion of distant metastases Performance status corresponding to ECOG grade 0-2 Tumor size clinically and radiologically ≤ 5cm, independent of hormone receptor and HER2 status Clinically and sonographically negative axillary lymph nodes before biopsy; core needle biopsy or fine needle aspiration of suspicious lymph node required BCS candidate with postoperative whole-breast irradiation and adequate systemic therapy No psychological and geographical restriction in follow-up Written informed consent  History of any cancer in the previous 5 years Bilateral breast cancer Invasive breast cancer treated with neoadjuvant therapy Tumor size clinically and radiologically > 5cm Mastectomy candidate Pregnancy and breastfeeding Male breast cancer Unable to understand and fill out questionnaires
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Locally Advanced Solid Tumor Metastatic Cancer Solid Tumor HER2-positive Gastric Cancer HER2-positive Metastatic Breast Cancer Signed informed consent Subjects must be ≥ 18 years of age Subject with advanced or metastatic solid tumors that is not amenable to surgical resection and is not eligible or has refused other approved therapeutic options that have demonstrated clinical benefit Histologically confirmed HER2 expression Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 Measurable or non-measurable evaluable disease according to 1.1 Adequate hematologic and end-organ function at baseline Oxygen saturation via pulse oxygenation ≥ 90% at rest on room air  Untreated central nervous system (CNS) metastases Multiple primary malignancies Clinically significant cardiovascular disease such as New York Heart Association (NYHA) cardiac disease (class III or greater) Pregnant or lactating female Serious, uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive study treatment History of autoimmune or immune mediated symptomatic disease Any anti-cancer chemotherapy or targeted small molecule therapy, or experimental therapy/device within 4 weeks or 5 half-lives of the drug prior to planned start of study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Burnout, Professional Physician employed by Cleveland Clinic Located in Ohio Must anticipate remaining employed for at least 6 months post-enrollment  Non-MD or non-DO healthcare providers Unable to commit to intervention sessions Current diagnosis of uncontrolled hypertension, and/or uncontrolled diabetes mellitus (defined as hemoglobin A1c ≥9%) Current or previous history of Cushing's disease or pheochromocytoma/paraganglioma
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Breast Cancer Female Breast Neoplasms • female and 18 years of age or older diagnosed with an early-stage (T1 or T2, and N0 or N1; according to the TNM-classification) invasive breast cancer eligible for breast conserving surgery  • Pregnancy or lactation Diabetes Multifocal tumor disease Diagnosis of inflammatory breast cancer Appointment at the nuclear medicine department for 18F-FDG administration would result in a unacceptable delay of surgery Subject has had exposure to ionizing radiation of more than 1 mSv in other research studies within the last 12 months Subject has recently (<60 days) or is simultaneously participating in another clinical trial
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Aortic Calcification Valve Aortic Valve Stenosis Patients who are candidates for aortic valve replacement. 2. Age greater than or equal to 18 years of age. 3. Both genders. 4. With any associated comorbidity 5. Any etiology 6. Hospitalized and with an echocardiographic study showing the variables to be studied 7. Informed Consent  Patients who have previously undergone other aortic valve surgery 2. Patients who have received contrast medium ≤24 hours. 3. Patients on hemodialysis. 4. Patients with infection. 5. Patients with cancer. 6. Patients with autoimmune diseases. 7. Pregnant women. 8. Patients who refuse to be included
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Cancer Quality of Life Patient Satisfaction Under the age of 65, suffering from unilateral (cT< 3cm) in situ or invasive breast cancer, who are fit for breast conserving surgeries, who had no previous breast surgery, independent from axillary surgery (sentinel lymph node biopsy or axillary block dissection)  In case the patient does not volunteer for the examination or the follow-ups Age above 65 years or poor general health condition, where the estimated life expectancies would be less than 2 years even without a tumor Malignant invasive tumor in the past history (except for non-melanoma skin tumors) Mastectomy performed due to positive resection margin Prior breast surgery (e.g. aesthetic surgery, breast lift) and/or radiotherapy on the breast or in the axilla Malignant tumor is not removed completely with pathological examination Severe non-surgical (e.g. radiotherapy) complication, which could influence the aesthetic and functional results Autoimmune diseases Tumor requiring mastectomy, or clinically larger than 3 cm tumor primary, or mastitis carcinomatosa, lymphangitis carcinomatosa Long-term steroid usage, which changed the skin's quality and structure
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-86.0,  Triple-negative Breast Cancer Age > 18 or <86 years of age, for Hispanic/Latino women we will use the National Advisory Committee on Racial, Ethnic and Other populations NAC definition which is (the ethnonyms "Hispanic" and "Latino" to refer collectively to the inhabitants of the United States of America who are of Latin American or Spanish origin-that is, Latino or Hispanic Americans). 2. Pre and Post menopausal women with histologically confirmed hormonal receptor negative (ER and/or PR <1%), Her2-neu negative (by IHC or/and FISH) invasive breast cancer stages I III or with metastatic triple-negative breast cancer (if develop metastatic disease during the chemotherapy or within 24 months after completion of all appropriate treatments). 3. Patient must be eligible for neo-adjuvant chemotherapy, and surgical lumpectomy or mastectomy. 4. All patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with Institutional and Federal guidelines  Women < 18 or >86 years of age 2. ER/PR positive, Her-2 neu positive breast cancer
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neurological Disorder All head MRI scans with compatible sequences > 18 years old  No corresponding radiologist report for the retrospective analyses No consent for future use of the research images held within the historic database stored at The Centre for Neuroimaging Sciences (Kings College London) Poor image quality
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Live Birth Rate Nulliparous women registered in Perinatal Services BC database with live birth between April 2008 and March 2018  multiparous women women with missing data in Perinatal Services BC database including gravid, parity, age, date of birth
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female at least 18 years old Histologically or cytologically confirmed breast carcinoma Patients planned to receive a breast-conserving surgery Patients received a preoperative breast magnetic resonance imaging Informed consent form understood and signed Patient agrees to all follow-up visits Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of study entry Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the surgery  Psychiatric or other condition that may interfere with the study Known allergy or contraindication to any study drug Patients received neoadjuvant therapies Patients received an excision biopsy of the tumor Breast feeding period Pregnant (female of childbearing potential only)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Breast Cancer Prevention Women between the ages of 18 and 80 Atypical hyperplasia or / and lobular carcinoma in situ confirmed by breast histology Women with breast cancer in first degree relatives Patients have better compliance with a series of research-related behaviors such as the upcoming comprehensive treatment and follow-up, and can understand and accept the research process of this study, and sign a written informed consent  Hepatorenal dysfunction, cardiovascular and cerebrovascular diseases Patients not suitable for this study judged by researchers
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Shoulder Osteoarthritis Arthropathy Shoulder Major patients and agreeing to participate in the study after oral and written information Care course patients for a reverse shoulder arthroplasty on a native shoulder joint  Patients under the age of 18 Patients refusing to participate in the study Patients whose condition does not allow informed consent Patients who are subject to legal protection (safeguarding of Justice, curatorship, guardianship), persons deprived of their liberty Unaffiliated patients and non-beneficiaries of a health insurance plan
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Critical Illness Nurse's Role Risk Factor Prognosis Being 18 or older Being in the intensive care unit for the first time To stay in the intensive care unit for at least 24 hours Being discharged from the intensive care unit in 90 days and less All information in the Patient Information Form can be accessed from the automation system  Being under the age of 18 Having previously slept in the intensive care unit Intensive care hospitalization has ended in less than 24 hours Staying in the intensive care unit for more than 90 days Failure to reach all questions in the Patient Information form from the automation system
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Invasive Breast Cancer Mastectomy, Segmental Margins of Excision Newly diagnosed women with biopsy-verified invasive breast cancer planned for breast conserving surgery Age > 18 year  Previous surgery for pre-malignant or malignant lesions in the breast Planned mastectomy
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women who are suspected or suspected of having breast cancer and who are advised to perform a detailed breast ultrasound or tissue sampling (biopsy) Classification into groups Group 1: Foreseen for BUS guided biopsy Group 2: BI-RADS classification I, II and III and foreseen for BUS only based diagnosis  Lactating women Women with mastitis Vulnerable persons
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Breast Cancer Breast-conserving Surgery Axillary Lymph Node Dissection Diagnosis of breast cancer scheduled for surgical treatment including conservative surgery and ALND Signed informed consent for ALND  Selective sentinel node biopsy negative Subsidiary mastectomy patients Denial of informed consent for axillary lymphadenectomy